Cromos Pharma, where the patients are

Archives

Choose a date range

From To

Choose one or more categories

Categories:



 


Karyopharm Therapeutics enters agreement with Clinipace Worldwide

Thursday, April 10, 2014 01:49 PM

Clinipace Worldwide, a global digital CRO (dCRO), has announced that Karyopharm Therapeutics, a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology and wound healing.

More... »

CRF Health eCOA webinar series

Greenphire, ERT partner to boost patient compliance for global clinical trials

Thursday, April 10, 2014 01:47 PM

Greenphire, a provider of payment technology for the clinical trial industry, has formed a strategic partnership with ERT, a global provider of high-quality patient safety and efficacy endpoint data collection. The partnership will integrate Greenphire's ClinCard System with ERT's best-in-class electronic patient reported outcomes (ePRO) technology.

More... »


ACRES, Verified Clinical Trials partner to promote clinical trial safety

Thursday, April 10, 2014 01:45 PM

Verified Clinical Trials (VCT) and the Alliance for Clinical Research Excellence and Safety (ACRES) have launched a partnership.

More... »

CEO Roundtable on Cancer launches data-sharing initiative to accelerate drug development

Thursday, April 10, 2014 01:03 PM

The CEO Roundtable on Cancer has launched Project Data Sphere, a new online oncology data-sharing platform using de-identified cancer patient information with the goal of accelerating drug discovery—by developing more efficient clinical trial protocols, epidemiological studies and, ultimately, new cancer therapies. 

More... »

Roche acquires IQuum to strengthen offerings in molecular diagnostics

Wednesday, April 9, 2014 12:40 PM

Roche has acquired IQuum, a privately held company focused on developing point-of-care offerings for the molecular diagnostics market. Roche will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.

More... »

EMA, Australian regulators strengthen collaboration in orphan medicines

Wednesday, April 9, 2014 12:38 PM

In a meeting at the EMA April 4, the EMA’s executive director, Guido Rasi, and the national manager of the Australian Therapeutic Goods Administration (TGA), John Skerritt, announced the two regulators have agreed to share the full assessment reports related to marketing authorizations of orphan medicines, intended to treat rare diseases.

More... »

WaveCheck receives $100,000 from Ontario Institute for Cancer Research

Wednesday, April 9, 2014 12:33 PM

WaveCheck has received a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide over two months last fall.

More... »

Lieber Institute forms consortium to develop brain disorder treatments

Wednesday, April 9, 2014 12:31 PM

The Lieber Institute for Brain Development (LIBD), an independent nonprofit, and pharmaceutical companies Astellas, Eli Lilly, Lundbeck, Pfizer and Roche are participating in an early-stage research consortium to analyze RNA, the genomic and epigenetic data obtained from human brains. The goal of the consortium is to expand knowledge around the genetic contribution to brain disorders in the hope of identifying potential new treatment options.

More... »

Daiichi Sankyo, UCSF collaborate on neurodegenerative diseases

Wednesday, April 9, 2014 12:27 PM

Daiichi Sankyo and UC San Francisco (UCSF) have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases.

More... »

TetraLogic to acquire Shape Pharmaceuticals

Wednesday, April 9, 2014 12:25 PM

TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, will acquire Shape Pharmaceuticals, a privately held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE), a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL), adding a second clinical-stage oncology compound to the TetraLogic portfolio.

More... »

CenterWatch Drugs in Clinical Trials
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs